{"id":58778,"date":"2024-01-25T19:06:41","date_gmt":"2024-01-25T18:06:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/catalent-commits-to-reducing-greenhouse-gas-emissions-by-2030\/"},"modified":"2024-01-25T19:06:41","modified_gmt":"2024-01-25T18:06:41","slug":"catalent-commits-to-reducing-greenhouse-gas-emissions-by-2030","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/catalent-commits-to-reducing-greenhouse-gas-emissions-by-2030\/","title":{"rendered":"Catalent Commits to Reducing Greenhouse Gas Emissions by 2030"},"content":{"rendered":"
\n

\nNew targets approved by Science Based Targets initiative (SBTi)<\/i><\/p>\n

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced its targets to reduce greenhouse gas emissions (Scope 1 and 2) by 42% by 2030. The company also committed to engaging with its suppliers, of purchased goods and services, capital goods, and upstream transportation and distribution, such that 70% of their emissions will have reduction goals aligned with science-based targets by the end of fiscal 2028. These targets have been validated by the Science Based Targets initiative (SBTi) and align to the organization\u2019s ambition to limit global temperature rise to 1.5\u00b0C above pre-industrial levels.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cOur mission to deliver products that help people live better lives goes hand in hand with our commitment to environmental responsibility and actions to limit climate change,\u201d said Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc. \u201cAs a leading contract manufacturing and development organization, it\u2019s important that we are guided by science-based targets and that we hold our partners accountable to the same standards so that we can make progress for a more sustainable future.\u201d<\/p>\n

\nBelow are Catalent\u2019s SBTi-approved targets:<\/p>\n